EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma

Ida Steiro, Synne Stokke Tryggestad, Eli Svorkdal Hess, Hanne Hella, Pegah Abdollahi, Kari Lenita Falck Moore, Margrete Friestad, Magne Børset, Tobias S Slørdahl, Anne Marit Sponaas

eJHaem · 2026-10 · 7 (5)

DOI: 10.1002/jha2.70388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 21.09.2026. Verfasst von Ida Steiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU) Trondheim…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Teknisk-Naturvitenskapelige Universitet.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bispecific antibody (BsAb) treatment can lead to increased infections in myeloma patients.

Methods

We used ELISpot and flow cytometry to test the T cell response to BCMA‐CD3‐bispecific T cell engager (BiTE) pavurutamab (PAV) and BCMA‐expressing myeloma cells after in vitro culture.

Results

Reduced pathogen‐specific responses were found in T cells cultured with PAV yet they killed myeloma cells. In an exploratory study, reduced pathogen‐specific memory T cell responses were detected in PBMCs from four myeloma patients responding to BCMA‐targeted BsAb therapy.

Conclusion

Our preliminary observation and its link to infection should be followed up in a larger study. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.

Autor:innen und Institutionen

  • Department of Clinical and Molecular Medicine Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU) Trondheim Norway.
  • Oslo Myeloma Center Department of Hematology Oslo University Hospital Oslo Norway.
  • KG Jebsen Center for B cell Malignancies Institute of Clinical Medicine University of Oslo Oslo Norway.
  • Department of Hematology and Oncology Stavanger University Hospital Stavanger Norway.
  • Institute of Clinical Medicine University of Oslo Oslo Norway.
  • Department of Immunology and Transfusion Medicine St. Olav's Hospital - Trondheim University Hospital Trondheim Norway.

Förderung

  • Norges Teknisk-Naturvitenskapelige Universitet

Zitieren

APA

Steiro, I., Tryggestad, S. S., Hess, E. S., Hella, H., Abdollahi, P., Moore, K. L. F., Friestad, M., Børset, M., Slørdahl, T. S., & Sponaas, A. M. (2026). Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma. eJHaem, 7(5). https://doi.org/10.1002/jha2.70388

Vancouver

Steiro I, Tryggestad SS, Hess ES, Hella H, Abdollahi P, Moore KLF, et al. Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma. eJHaem. 2026;7(5). doi:10.1002/jha2.70388

BibTeX
@article{Steiro2026,
  author = {Steiro, Ida and Tryggestad, Synne Stokke and Hess, Eli Svorkdal and Hella, Hanne and Abdollahi, Pegah and Moore, Kari Lenita Falck and Friestad, Margrete and Børset, Magne and Slørdahl, Tobias S and Sponaas, Anne Marit},
  title = {Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {5},
  doi = {10.1002/jha2.70388}
}
Kostenlos starten →